🔗 Share this article

Given that the United States proceeds with unprecedented revisions to its immunization schedules, an unexpected name has emerged in a surprising turn: Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by casting doubt on Covid shots during the pandemic and has focused upon potential deaths following COVID-19 immunization in her brief time at the Food and Drug Administration.

Scheduled Overhauls to Childhood Vaccine Schedule

Health officials had intended to unveil radical revisions to the childhood vaccine schedule recently, synchronizing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of alignment with a large portion of the global community with little proof for public health gain. The planned update has been delayed until the next year.

Instead of the director of the vaccine center, Dr. Høeg is scheduled to address the audience at the event. She was recently named acting director of the FDA’s CDER, the fifth person to head the center this year.

A Shift at the Agency

Høeg's temporary position may indicate a closer partnership between the pharmaceutical and biologics branches as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon reevaluating previously authorized vaccines at the FDA.

Høeg has frequently advocated for discontinuing certain pediatric vaccine recommendations in the US in order to be more in line with the Danish model, a country with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

To date public appearances, she has persisted in emphasizing on vaccination policy – typically the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to drug regulation.

Doubts Over Background

Høeg has no obvious experience in pharmaceutical research, regulation or leadership, which has been customary for past leaders of the biologics center. She has worked at the FDA as a senior adviser to the FDA chief and the vaccine center since earlier this year.

“She appears not to have any of the qualifications” for overseeing the pharmaceutical oversight division, remarked Jonathan Howard. “She’s never run a scientific study. She is not versed in leading a sizeable institution. She is not an expert in drug approvals.”

Previous directors of the center would “understand laws and regulations and the science of medication creation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who led CBER have had.”

CDER has an vast portfolio at the agency, the former commissioner emphasized.

“The public just zeroes in on the new drug program, but the generic drug division clears a multitude of off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and so forth, and every single one have to be managed,” Dr. Woodcock noted. “The responsibility you neglect, that is precisely what that I always told people is going to bite you.”

Additionally, a major administrative component to the position, which manages over 5,000 staff members. “It is a enormous administrative position, if you execute it properly,” she added.

Agency Reaction and Disputed Policies

In response to questions about Høeg’s fitness for the role and whether this appointment represents greater collaboration among regulatory chiefs on vaccines, a press secretary responded that the “inquiries stem from flawed premises”.

“Her resume matches the responsibilities of her role,” the spokesperson stated, noting the period Høeg spent counseling the FDA commissioner on “drug safety and regulatory science, including computerized risk analysis and shot safety tracking”.

As the temporary head, Høeg takes over the commissioner’s new expedited review system, a controversial rapid drug-approval program that allegedly troubled her preceding directors. “How are these drugs being chosen for this voucher program? Who makes the calls?” Dr. Howard questioned. “There is a lot of lack of transparency going on at the regulatory body right now.”

In general, he stated, “the agency seems to be moving towards less stringent rules of pharmaceuticals, except for vaccines.”

Established History on Vaccines

Concerning immunizations, Dr. Høeg has a more documented, if troubling, track record, some experts have noted. She released a study using unconfirmed volunteer-provided data to estimate the frequency of heart inflammation following Covid immunization. She advised the Florida chief medical officer Dr. Joseph Ladapo, who was said to have modified findings to indicate Covid vaccines are more dangerous than they are.

Part of her “wish list” for the incoming administration included changing regulations for new vaccines and ending “optional” vaccines, she said after the election on a podcast. At the agency, Dr. Høeg has reportedly suggested preventing young men from getting COVID-19 vaccines.

“She’s an all-around true believer who commences with her beliefs and tailors the evidence to retrofit the evidence in a highly misleading, dishonest manner,” Howard argued.

Taking Control and a “Push for Payback”

Høeg became part of other contrarians, {like|